Remove Disease Remove Nurses Remove Treatment
article thumbnail

Drop in COVID Cases Seen in Nursing Homes as U.S. Vaccine Effort Makes Headway

The Pharma Data

1, 2021 — As America’s vaccination campaign begins to gain momentum, a promising sign has emerged: Federal data shows that coronavirus cases in nursing homes have declined over the past four weeks. The country recorded 17,584 cases in nursing homes during the week ending Jan. Centers for Disease Control and Prevention.

Nurses 52
article thumbnail

Behçet’s Disease: Diverse manifestations in both brain and body

On Medicine

Behçet’s disease is a rare multisystem vasculitic disorder that can affect any of the blood vessels of the body; signs and symptoms are diverse among individuals and range in severity, but often present as recurrent oral aphthous ulcers, genital ulcers, or as complications involving the eyes.

Disease 40
article thumbnail

Topical Gene Therapy FDA-Approved for Severe Skin Disease, Dystrophic Epidermolysis Bullosa

PLOS: DNA Science

The gene treatment has been a long time coming, but it differs from the handful of other approved gene therapies: it isn’t a one-and-done. Peter Marinkovich, MD, director of the Blistering Disease Clinic at Stanford Health Care, calls DEB a devastating disease. Earlier results were published in Nature Medicine.

article thumbnail

CARVYKTI® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

The Pharma Data

In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients who responded experienced a stringent complete response . In December 2017, Janssen Biotech, Inc. to develop and commercialise cilta-cel.[1].

article thumbnail

Benefits of Participating in Clinical Trials

Olympian Clinical Research

Clinical trials are essential for advancing medical knowledge and developing new treatments that can improve patient care and outcomes. They are the primary way researchers discover whether new treatments, like drugs, diets, or medical devices, are safe and effective in humans.

article thumbnail

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults

The Pharma Data

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults Teva Pharmaceuticals, a U.S. The initiation of treatment requires no loading dose or oral supplementation.

article thumbnail

Tampa General Hospital is First in Florida To Offer Monoclonal Antibody Treatments to COVID-19 Patients

The Pharma Data

18, 2020 /PRNewswire/ — Tampa General Hospital provided the first monoclonal antibody treatment to a COVID-19 positive patient today. This single dose infusion-based treatment is provided on an outpatient basis and marks a dramatic shift in COVID-19 care. Currently receiving immunosuppressive treatment.